PTC Therapeutics Initiates Two Clinical Trials Of PTC299 In Cancer Patients

PTC Therapeutics, Inc. (PTC) announced the initiation of two clinical trials of the company's product candidate PTC299 in adult patients with solid tumor cancers and Kaposi Sarcoma, a HIV-related cancer. PTC299 is an orally delivered, investigational new drug that offers an innovative approach to anti-angiogenesis, limiting the formation of new blood vessels for tumors.